Karl J. Puttlitz

Array ( [id] => 20817658 [patent_doc_number] => 12673112 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-07 [patent_title] => CCR8 antibodies, antibody conjugates, and uses thereof [patent_app_type] => utility [patent_app_number] => 19/412448 [patent_app_country] => US [patent_app_date] => 2025-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 30 [patent_no_of_words] => 49720 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19412448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20749279 [patent_doc_number] => 20260151497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-06-04 [patent_title] => LIGAND-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 19/407141 [patent_app_country] => US [patent_app_date] => 2025-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 280 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19407141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20735594 [patent_doc_number] => 20260144884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-28 [patent_title] => ANTI-LRRC15 ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 19/397449 [patent_app_country] => US [patent_app_date] => 2025-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19397449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20777977 [patent_doc_number] => 20260166170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-06-18 [patent_title] => ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR AND ITS USE [patent_app_type] => utility [patent_app_number] => 19/368460 [patent_app_country] => US [patent_app_date] => 2025-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19368460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20517681 [patent_doc_number] => 20260041784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-12 [patent_title] => COMPOSITIONS FOR TARGETING MUSCLE CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/299229 [patent_app_country] => US [patent_app_date] => 2025-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19299229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20472047 [patent_doc_number] => 20260014265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-15 [patent_title] => TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) [patent_app_type] => utility [patent_app_number] => 19/265621 [patent_app_country] => US [patent_app_date] => 2025-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19265621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20406422 [patent_doc_number] => 20250375531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-11 [patent_title] => TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECAN [patent_app_type] => utility [patent_app_number] => 19/255499 [patent_app_country] => US [patent_app_date] => 2025-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19255499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20099030 [patent_doc_number] => 20250228966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-17 [patent_title] => LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 19/171920 [patent_app_country] => US [patent_app_date] => 2025-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19171920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20308064 [patent_doc_number] => 20250325693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-23 [patent_title] => ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 50 SKIPPING [patent_app_type] => utility [patent_app_number] => 19/097573 [patent_app_country] => US [patent_app_date] => 2025-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19097573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20178351 [patent_doc_number] => 20250262309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS [patent_app_type] => utility [patent_app_number] => 19/078822 [patent_app_country] => US [patent_app_date] => 2025-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19078822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20192342 [patent_doc_number] => 20250269052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => ANTI-CEACAM5 ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 19/064273 [patent_app_country] => US [patent_app_date] => 2025-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46745 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19064273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19890367 [patent_doc_number] => 20250115679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-10 [patent_title] => BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/957324 [patent_app_country] => US [patent_app_date] => 2024-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18957324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20505930 [patent_doc_number] => 12540197 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-03 [patent_title] => Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates [patent_app_type] => utility [patent_app_number] => 18/914023 [patent_app_country] => US [patent_app_date] => 2024-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 89138 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 350 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18914023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20239660 [patent_doc_number] => 12419964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload [patent_app_type] => utility [patent_app_number] => 18/904628 [patent_app_country] => US [patent_app_date] => 2024-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 15223 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18904628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19982863 [patent_doc_number] => 20250121085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 45 SKIPPING [patent_app_type] => utility [patent_app_number] => 18/903935 [patent_app_country] => US [patent_app_date] => 2024-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40976 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18903935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19722816 [patent_doc_number] => 20250025567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND [patent_app_type] => utility [patent_app_number] => 18/896098 [patent_app_country] => US [patent_app_date] => 2024-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 273 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18896098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19641455 [patent_doc_number] => 20240415975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAME [patent_app_type] => utility [patent_app_number] => 18/802353 [patent_app_country] => US [patent_app_date] => 2024-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18802353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613280 [patent_doc_number] => 20240398960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/787110 [patent_app_country] => US [patent_app_date] => 2024-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18787110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19496535 [patent_doc_number] => 20240335553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => Fc GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 18/753148 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18753148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613302 [patent_doc_number] => 20240398982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/731223 [patent_app_country] => US [patent_app_date] => 2024-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18731223 [rel_patent_id] =>[rel_patent_doc_number] =>)